Resverlogix Corp T.RVX

Alternate Symbol(s): RVXCF

Healthcare Biotechnology

Resverlogix Corp. is a Canada-based late-stage biotechnology company. The Company is engaged in epigenetics, with a focus on developing therapies for the benefit of patients with chronic diseases. Its epigenetic therapies are designed to regulate the expression of disease-causing genes. The Company's clinical program is focused on evaluating its lead candidate apabetalone (RVX-208) for the treatment of cardiovascular disease and associated comorbidities, and post-COVID-19 conditions. RVX-208 is a small molecule that is a selective bromodomain and extra-terminal (BET) inhibitor. BET bromodomain inhibition is an epigenetic mechanism that can regulate disease-causing genes. RVX-208 is a BET inhibitor selective for the second bromodomain (BD2) within the BET proteins. It partners with EVERSANA, to support the commercialization of RVX-208 for cardiovascular disease, post-COVID-19 conditions, and pulmonary arterial hypertension in Canada and the United States.

TSX:RVX - Post by User

Resverlogix Corp

Bullboard Posts

Comment by ledrogon Aug 15, 2018 3:55pm

169 Views

Post# 28467466

RE:RE:RE:RE:RE:RE:RE:RE:Feeling depressed maybe? Look at this chart:

When the Rothschild news and the 7th DSMB thumbs up came out...someone had to be selling...buyers need someone willing to supply the shares they want, and if there aren't any sellers there's always the chance that demand will be met by going short.

we'll see what the number say.

Bullboard Posts

Building on success: Silvercorp’s acquisition of Adventus